IL309053A - Methods for treating atopic dermatitis and related disorders - Google Patents

Methods for treating atopic dermatitis and related disorders

Info

Publication number
IL309053A
IL309053A IL309053A IL30905323A IL309053A IL 309053 A IL309053 A IL 309053A IL 309053 A IL309053 A IL 309053A IL 30905323 A IL30905323 A IL 30905323A IL 309053 A IL309053 A IL 309053A
Authority
IL
Israel
Prior art keywords
methods
atopic dermatitis
related disorders
treating atopic
treating
Prior art date
Application number
IL309053A
Other languages
English (en)
Hebrew (he)
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of IL309053A publication Critical patent/IL309053A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL309053A 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders IL309053A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108379.5A GB202108379D0 (en) 2021-06-11 2021-06-11 Methods for treating a topic dermatitis and related disorders
PCT/EP2022/065851 WO2022258814A1 (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders

Publications (1)

Publication Number Publication Date
IL309053A true IL309053A (en) 2024-02-01

Family

ID=76954592

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309053A IL309053A (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders

Country Status (9)

Country Link
US (1) US20250059269A1 (https=)
EP (1) EP4351641A1 (https=)
JP (1) JP2024522620A (https=)
AU (1) AU2022289697A1 (https=)
CA (1) CA3221119A1 (https=)
GB (1) GB202108379D0 (https=)
IL (1) IL309053A (https=)
TW (1) TW202317184A (https=)
WO (1) WO2022258814A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026508149A (ja) * 2023-02-13 2026-03-10 インターベット インターナショナル ベー． フェー． イヌｉｌ－１３に対するイヌ抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Also Published As

Publication number Publication date
TW202317184A (zh) 2023-05-01
CA3221119A1 (en) 2022-12-15
AU2022289697A1 (en) 2023-12-21
JP2024522620A (ja) 2024-06-21
GB202108379D0 (en) 2021-07-28
EP4351641A1 (en) 2024-04-17
WO2022258814A1 (en) 2022-12-15
US20250059269A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
IL288061A (en) Compounds and methods for the treatment of covid-19
IL290455A (en) Methods of treating psychological and brain disorders
IL304429A (en) Methods and compositions for treatment of epileptic disorders
IL280919A (en) Methods of treating aging-related disorders
IL291687A (en) Methods for treating myelofibrosis and related conditions
PL3865102T3 (pl) Urządzenie i sposób leczenia zaburzeń neurologicznych układu słuchowego
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
IL265666A (en) A safe and effective method for the treatment of eczema with a specific anti-il23 antibody
IL294594A (en) Methods of treating pemphigus
IL262660A (en) Preparations for and method of treating acid-base disorders
IL262803B (en) Methods of treating circadian rhythm sleep disorders
IL285627A (en) Systems and methods for the treatment of symptoms associated with migraines
EP3471746A4 (en) METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
IL313097A (en) Methods of treating cns disorders
EP3784280A4 (en) TREATMENT OF ATOPIC DERMATITIS
SG11202003453QA (en) Method of treating acid-base disorders
EP4231000A4 (en) PREDICTION METHOD AND PREDICTION DEVICE
EP3436427A4 (en) METHOD AND COMPOSITION FOR TREATING NEURONIC HYPERREMARKABILITY
IL310701A (en) Treatment of atopic dermatitis
IL309053A (en) Methods for treating atopic dermatitis and related disorders
EP4167037A4 (en) PREDICTION SCORE CALCULATION DEVICE, PREDICTION SCORE CALCULATION METHOD, PREDICTION SCORE CALCULATION PROGRAM, AND LEARNING DEVICE
IL313539A (en) Methods for treating neurological disorders
MA51647A (fr) Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement
IL311581A (en) Compositions and methods for the treatment of pcdh19 related disorders
EP3592423A4 (en) METHOD FOR TREATMENT OF PELVIC PAIN, CHRONIC PROSTATITIS AND / OR SYMPTOMS OF AN OVERACTIVE BLADDER